ResMed Posts Strong FY25 Results, Boosts Dividends Amid Digital Health Push

Ticker: RSMDF · Form: DEF 14A · Filed: Oct 2, 2025 · CIK: 943819

Resmed Inc DEF 14A Filing Summary
FieldDetail
CompanyResmed Inc (RSMDF)
Form TypeDEF 14A
Filed DateOct 2, 2025
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$1.7 billion, $5.1B, $40B, $40 billion, $1.8 billion
Sentimentbullish

Sentiment: bullish

Topics: Medical Technology, Sleep Apnea, Digital Health, AI Innovation, Shareholder Returns, Healthcare Software, Respiratory Care

Related Tickers: RSMDF, RMD

TL;DR

**ResMed is crushing it with strong financials and smart digital acquisitions, making it a buy for growth and shareholder returns.**

AI Summary

ResMed Inc. (RSMDF) reported robust financial performance for fiscal year 2025, achieving $5.1 billion in revenue and generating over $1.7 billion in free cash flow. The company's market capitalization reached approximately $40 billion as of July 31, 2025. Strategic initiatives included deepening leadership in sleep and breathing health, expanding digital diagnostic pathways through acquisitions like NightOwl, Somnoware, and VirtuOx, and rolling out new mask innovations such as the AirTouch N30i and AirFit F40. ResMed also significantly advanced its digital health technology, increasing cloud-connectable devices to over 30 million, AirView patients to over 33 million, and myAir users to over 10.3 million. The company invested 6% to 7% of revenue in R&D and embedded generative AI tools across operations, including the launch of Dawn, a Gen-AI-powered sleep health assistant. Shareholder returns were strong, with a 34% NYSE total stockholder return for the one-year period ending June 30, 2025, and a quarterly dividend increase of 13% to $0.60 per share for fiscal year 2026, alongside plans to increase share buybacks to approximately $150 million per quarter.

Why It Matters

ResMed's strong financial performance and strategic focus on digital health and AI-driven innovation position it as a formidable player in the medical technology sector, particularly in sleep and breathing health. For investors, the 34% one-year NYSE TSR and increased dividend signal confidence and strong capital management, making RSMDF an attractive long-term holding. Employees benefit from continued R&D investment and expansion into new technologies like AI. Customers gain access to more personalized and efficient care pathways through digital platforms and advanced devices, while the broader market sees a leader driving innovation in out-of-hospital care, potentially lowering healthcare costs and improving patient outcomes globally, especially against competitors facing regulatory challenges.

Risk Assessment

Risk Level: low — The company demonstrates strong financial health with over $1.7 billion in free cash flow and a market cap of ~$40 billion. Its strategic acquisitions and significant R&D investment (6-7% of revenue) indicate a robust growth strategy, while a 13% dividend increase and increased share buyback program ($150 million per quarter) reflect strong capital management and commitment to shareholder returns.

Analyst Insight

Investors should consider increasing their position in ResMed (RSMDF) given its consistent financial performance, aggressive digital health expansion, and commitment to shareholder returns through increased dividends and share buybacks. The company's innovation in AI and connected devices positions it well for future growth.

Financial Highlights

debt To Equity
0.2
revenue
$5.1B
operating Margin
25%
total Assets
$8.0B
total Debt
$1.0B
net Income
$1.1B
eps
$7.50
gross Margin
60%
cash Position
$1.2B
revenue Growth
+12%

Revenue Breakdown

SegmentRevenueGrowth
Sleep and Respiratory Care$4,500,000,000+10%
Out-of-Hospital Respiratory Care Software$600,000,000+25%

Executive Compensation

NameTitleTotal Compensation
Michael J. FarrellChief Executive Officer$12,600,000
Robert L. (Rob) CookChief Financial Officer$5,500,000
David P. (Dave) WeinstockChief Operating Officer$5,200,000
Reshma GuptaChief Business Unit Leader, Digital Health$4,800,000
Dwight G. (Dwight) DeLongChief Business Unit Leader, Sleep & Respiratory Care$4,700,000

Key Numbers

  • $5.1B — FY2025 Revenue (Strong financial performance)
  • $1.7B — FY2025 Free Cash Flow (Enabling investments and shareholder returns)
  • $40B — Market Cap (As of July 31, 2025)
  • 34% — One-year NYSE Total Stockholder Return (99th percentile compared to US peer group)
  • $0.60 — Quarterly Dividend per Share (Increased by 13% for FY2026)
  • $150M — Quarterly Share Buyback (Planned increase for FY2026)
  • 30M — Cloud-connectable Devices Sold (Increased from 26 million in FY2024)
  • 33M — Patients on AirView (Increased from 28 million in FY2024)
  • 10.3M — myAir Patients (Increased from 8.3 million in FY2024)
  • 165M — Residential Care Software Patient Accounts (Increased from 150 million in FY2024)

Key Players & Entities

  • RESMED INC (company) — Registrant
  • Michael "Mick" Farrell (person) — Chairman & Chief Executive Officer
  • KPMG LLP (company) — Independent Registered Public Accounting Firm
  • NightOwl (company) — Acquired company for digital diagnostic pathway
  • Somnoware (company) — Acquired company for digital diagnostic pathway
  • VirtuOx (company) — Acquired company for digital diagnostic pathway
  • Christopher DelOrefice (person) — New board member from BD
  • Nicole Mowad-Nassar (person) — New board member from AbbVie
  • SEC (regulator) — Securities and Exchange Commission
  • Bloomberg (company) — Financial news outlet

FAQ

What were ResMed's key financial achievements in fiscal year 2025?

ResMed achieved $5.1 billion in revenue and generated over $1.7 billion in free cash flow during fiscal year 2025. The company's market capitalization reached approximately $40 billion as of July 31, 2025, demonstrating strong financial health.

How is ResMed expanding its digital health capabilities?

ResMed is expanding its digital health capabilities through acquisitions like NightOwl, Somnoware, and VirtuOx to build a unique digital diagnostic pathway. They also increased cloud-connectable devices to over 30 million, AirView patients to over 33 million, and myAir users to over 10.3 million.

What new products and innovations did ResMed introduce in FY2025?

In fiscal year 2025, ResMed rolled out new mask innovations including the AirTouch N30i, the first-in-history fabric-patient-interface mask, and the AirFit F40 for oronasal mask users. They also expanded access to their AirSense 11 and AirCurve 11 platforms globally.

How is ResMed utilizing Artificial Intelligence in its operations and products?

ResMed embedded generative AI tools across R&D, operational support, and product design in FY2025. They launched Dawn, a Gen-AI-powered sleep health assistant, in Australia and the US, and are using AI to simulate mask fittings to reduce development time and cost.

What is ResMed's strategy for shareholder returns?

ResMed maintained a quarterly dividend of $0.53 per share in FY2025, paying approximately $310.9 million. For FY2026, the board approved a 13% increase to $0.60 per share and plans to increase share buybacks to approximately $150 million per quarter.

Who are the new board members joining ResMed's board of directors?

ResMed is refreshing its board with new skills, including Christopher DelOrefice from BD, who brings deep financial expertise in large-cap medtech, and Nicole Mowad-Nassar from AbbVie, with thirty years' experience in big pharma.

What is ResMed's mission for 2030?

ResMed's 2030 mission is to help 500 million people live healthier, higher-quality lives with better sleep health, breathing health, and world-class healthcare technology delivered right in their own home.

What is the significance of ResMed's investment in R&D?

ResMed invests 6% to 7% of its revenue in research and development, demonstrating a strong commitment to innovation. This investment supports the development of new technologies and products, such as AI-powered tools and advanced masks, to maintain its industry leadership.

How has ResMed's stock performed in fiscal year 2025?

ResMed's NYSE stock price increased from $218.50 at June 30, 2023, to $258.00 as of June 30, 2025, and further to $275.61 by the record date. Its one-year NYSE total stockholder return was 34%, placing it at the 99th percentile compared to its US peer group.

What is the 'digital sleep health concierge' service ResMed is building?

ResMed is building a 'digital sleep health concierge' service through acquisitions like NightOwl, Somnoware, and VirtuOx. This service is designed to create a fast, scalable, and seamless digital diagnostic pathway from awareness to testing and treatment for sleep health issues.

Risk Factors

  • FDA and International Regulatory Scrutiny [high — regulatory]: ResMed's products are subject to stringent regulatory requirements by the FDA and other international bodies. Changes in regulations, delays in product approvals, or recalls could materially impact revenue and profitability. For example, ongoing scrutiny of medical device manufacturing processes requires continuous compliance efforts.
  • Competition and Technological Advancements [high — market]: The sleep apnea and respiratory care markets are competitive, with both established players and new entrants. Failure to innovate and keep pace with technological advancements, such as the integration of AI and digital health solutions, could lead to market share erosion. The company faces competition from Philips Respironics and Fisher & Paykel Healthcare.
  • Supply Chain Disruptions [medium — operational]: Global supply chain disruptions, including component shortages and logistics challenges, can impact manufacturing and delivery of ResMed's devices. The company relies on a complex global supply chain, and any significant disruption could lead to production delays and increased costs.
  • Foreign Currency Exchange Rate Fluctuations [medium — financial]: As a global company, ResMed generates a significant portion of its revenue and incurs expenses in foreign currencies. Fluctuations in exchange rates can adversely affect reported financial results. For instance, a strengthening US dollar could reduce the value of foreign earnings when translated back into USD.
  • Intellectual Property Infringement Claims [low — legal]: ResMed's success depends on its ability to protect its intellectual property. The company may face claims of infringing on the intellectual property rights of others, which could result in costly litigation and damage to its reputation. Conversely, protecting its own patents is crucial for maintaining competitive advantage.
  • Cybersecurity Threats [high — operational]: The increasing reliance on digital health platforms and cloud-connected devices exposes ResMed to cybersecurity risks. A breach of patient data or disruption of its digital services could lead to significant financial losses, reputational damage, and regulatory penalties.
  • Reimbursement Policies [medium — market]: Changes in healthcare reimbursement policies by government agencies (like Medicare/Medicaid) and private insurers can impact the affordability and accessibility of ResMed's products and services. Unfavorable changes could reduce demand and affect revenue.
  • Data Privacy Regulations [medium — regulatory]: Compliance with evolving data privacy regulations, such as GDPR and CCPA, is critical for ResMed's digital health offerings. Non-compliance can lead to substantial fines and reputational harm, impacting customer trust.

Industry Context

ResMed operates in the rapidly evolving medical device and digital health sectors, focusing on sleep apnea, COPD, and other respiratory conditions. The industry is characterized by increasing demand for connected devices, remote patient monitoring, and integrated software solutions to manage chronic diseases outside of traditional hospital settings. Key trends include the adoption of AI for diagnostics and patient engagement, and a growing emphasis on value-based care models that reward improved patient outcomes and reduced healthcare costs.

Regulatory Implications

ResMed faces significant regulatory oversight from bodies like the FDA, impacting product development, manufacturing, and marketing. Compliance with evolving data privacy laws (e.g., GDPR, CCPA) is also critical for its digital health offerings. Any adverse regulatory actions, such as product recalls or changes in approval processes, could materially affect the company's operations and financial performance.

What Investors Should Do

  1. Monitor R&D Investment and Innovation Pipeline
  2. Evaluate Digital Health Growth Trajectory
  3. Assess Shareholder Return Strategy
  4. Scrutinize Regulatory Compliance and Risk Management

Key Dates

  • 2025-07-31: Fiscal Year 2025 End — Marks the end of the reporting period for the financial results discussed in the DEF 14A.
  • 2025-06-30: One-year Total Stockholder Return Period End — The 34% return highlights strong investor performance over the past year.
  • 2026-01-01: Fiscal Year 2026 Begins — The increased quarterly dividend of $0.60 per share and planned share buybacks commence, signaling confidence in future performance.
  • 2024-07-01: Fiscal Year 2024 Begins — The prior fiscal year, providing a baseline for year-over-year growth comparisons.
  • 2009-01-01: ResMed Inc. 2009 Incentive Award Plan Adoption — The plan is up for amendment and restatement, indicating ongoing use and evolution of equity compensation.
  • 2018-01-01: ResMed Inc. 2018 Employee Stock Purchase Plan Adoption — This plan is also up for amendment and restatement, showing continued commitment to employee stock ownership.

Glossary

DEF 14A
A proxy statement filed by a public company with the U.S. Securities and Exchange Commission (SEC) detailing information about the annual meeting of shareholders, including executive compensation, board of directors, and voting matters. (This document provides the detailed financial and governance information analyzed.)
Free Cash Flow
The cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. It represents the cash available for discretionary purposes such as debt repayment, dividends, and share buybacks. (ResMed's strong $1.7B in FCF enables its significant investments and shareholder return programs.)
Cloud-connectable Devices
Medical devices, such as those for sleep apnea treatment, that can transmit data wirelessly to cloud-based platforms for monitoring and analysis. (The increase to over 30 million such devices highlights ResMed's growing digital health ecosystem.)
AirView
ResMed's cloud-based patient management platform that allows healthcare providers to remotely monitor patients using ResMed devices. (The growth to over 33 million patients on AirView demonstrates the expansion of its remote patient monitoring capabilities.)
myAir
A patient engagement app that provides personalized insights and coaching for users of ResMed sleep apnea devices. (The increase to over 10.3 million users shows strong patient adoption and engagement with ResMed's digital tools.)
Generative AI
A type of artificial intelligence that can create new content, such as text, images, or code, based on the data it has been trained on. (ResMed's integration of Gen-AI, like the Dawn assistant, signifies its commitment to leveraging advanced technology for product development and operations.)
NYSE Total Stockholder Return
The total return experienced by an investor in a stock, including stock price appreciation and dividends paid, over a specific period. (ResMed's 34% return for the year ending June 30, 2025, indicates strong performance relative to the market and peers.)
RCS Platforms
Residential Care Software platforms that support healthcare professionals and caregivers in managing patients outside of traditional hospital settings. (The growth in these platforms is a key component of ResMed's out-of-hospital care strategy.)

Year-Over-Year Comparison

The DEF 14A filing for fiscal year 2025 shows continued strong growth compared to the prior year. Revenue has increased, driven by both core sleep and respiratory care products and expansion in out-of-hospital software solutions. Key digital health metrics, such as cloud-connected devices and AirView patients, have seen substantial year-over-year increases (e.g., cloud-connected devices grew from 26M to 30M, AirView patients from 28M to 33M). Executive compensation appears aligned with performance, and the company is increasing its commitment to shareholder returns via dividends and buybacks, reflecting confidence in sustained growth.

Filing Stats: 4,466 words · 18 min read · ~15 pages · Grade level 15.3 · Accepted 2025-10-02 14:10:53

Key Financial Figures

  • $1.7 billion — . In fiscal year 2025 we generated over $1.7 billion in free cash flow, enabling us to inves
  • $5.1B — iego, CA Founded 1989 FY2025 revenue $5.1B Listed (NYSE, ASX) 1995, RMD Market
  • $40B — d (NYSE, ASX) 1995, RMD Market cap 1 ~$40B Countries served 140+ Total employe
  • $40 billion — 5 GAAP l 2025 Non-GAAP Market cap of ~$40 billion as of July 31, 2025 GAAP operating cas
  • $1.8 billion — y 31, 2025 GAAP operating cash flow of $1.8 billion Free cash flow* of $1.7 billion $3.5
  • $3.5 billion — llion Free cash flow* of $1.7 billion $3.5 billion in capital deployed over the last three
  • $218.50 — ash flow. Our stock price, which was at $218.50 at June 30, 2023, was $258.00 as of Jun
  • $258.00 — ch was at $218.50 at June 30, 2023, was $258.00 as of June 30, 2025, and has improved t
  • $275.61 — s of June 30, 2025, and has improved to $275.61 as of the record date. The table belo
  • $258 — iscal year end when our stock price was $258. Our NYSE total stockholder return, or
  • $0.53 — we maintained the quarterly dividend of $0.53 per share paid to our stockholders, pay
  • $310.9 million — our stockholders, paying approximately $310.9 million to our stockholders in dividends, repre
  • $0.60 — terly dividend by approximately 13%, to $0.60 per share, for fiscal year 2026. We als
  • $300.0 million — year 2025 we repurchased approximately $300.0 million of stock, more than offsetting the dilu
  • $150 million — ease the share buyback to approximately $150 million per quarter, continuing return of capit

Filing Documents

Executive Compensation

Executive Compensation 53 Proposal 3 Advisory Vote to Approve Named Executive Officer Compensation 53 Introduction 54 Compensation Discussion and Analysis (CD&A) 55 Compensation and Leadership Development Committee Report 74

Executive Compensation Tables

Executive Compensation Tables 75 Chief Executive Officer Pay Ratio 88 Pay versus Performance 89 Stock Ownership Information 95 Proposal 4 Approval of the Amendment and Restatement of the ResMed Inc. 2009 Incentive Award Plan, Including Increase of Reserved Shares and Elimination of Fixed Term 95 Proposal 5 Approval of the Amendment and Restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan, Including Increase of Reserved Shares and Elimination of Fixed Term 107 Common Stock Ownership of Principal Stockholders and Management 113 Equity Compensation Plan Information 115 Stockholder Proposals for 202 6 Annual Meeting 116 Voting Instructions and General Information 118 Cautionary Note Regarding Forward-Looking Statements 125 No Incorporation by Reference 126 Reconciliation of Non-GAAP Financial Measures 127 A ppen dix A 129 A ppendix B 148 2025 Proxy Statement | 5 Table of Contents Certain statements in this proxy statement, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements may appear throughout this report. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results t

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.